MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Survival outcomes favored the higher dose: more than 93% of patients in the 70 Gy group were alive one year after treatment, ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

“The data from this latest publication from our collaborators at UdeM further validates the potential benefit of CryptoMap ...

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...